Whole Genome Pharmacogenomics Study Of Susceptibility Of Birth Defects In Children Born To Mothers Taking Anti-Epileptic Drugs
Funder
National Health and Medical Research Council
Funding Amount
$663,160.00
Summary
This project will investigate for genes that determine why certain women have an increased risk of having a baby with a birth defect if they become pregnant while being treated with a medication for epilepsy. Subjects will be recruited from the Australian Pregnancy Register, the findings validated using subjects from the UK Epilepsy and Pregnancy Register. The study will comprehensively examine for both common and rare changes in genes across the entire human genome.
Pharmacogenomics And Mechanistic Basis Of Drug Hypersensitivity
Funder
National Health and Medical Research Council
Funding Amount
$677,220.00
Summary
Drug allergy causes physical harm, anxiety and may limit treatment options. We introduced personalised genetic testing to prevent one such drug hypersensitivity. Genetic information from patients who have had adverse drug reactions will be used to work out how drugs trigger severe allergic reactions and develop strategies to predict these reactions and design safer drugs. This research has relevance to our understanding of other inflammatory disease such as autoimmune disease and multiple sclero ....Drug allergy causes physical harm, anxiety and may limit treatment options. We introduced personalised genetic testing to prevent one such drug hypersensitivity. Genetic information from patients who have had adverse drug reactions will be used to work out how drugs trigger severe allergic reactions and develop strategies to predict these reactions and design safer drugs. This research has relevance to our understanding of other inflammatory disease such as autoimmune disease and multiple sclerosis.Read moreRead less
Genomics Of Antiepileptic Drug-induced Stevens Johnson Syndrome
Funder
National Health and Medical Research Council
Funding Amount
$500,817.00
Summary
Epilepsy affects 3% of people. Severe skin reactions to anti-epileptic drugs are unpredictable and potentially fatal. This project aims to better understand the complex genetic architecture of these reactions using the latest sequencing platforms applied to a unique collection of samples, followed by functional analysis. The findings will enhance the practice of precision medicine in epilepsy treatment, shed light on the mechanisms of these reactions, and inform better drug design in the future.
Kava For The Treatment Of Generalized Anxiety Disorder: A 16-Week Double-Blind RCT
Funder
National Health and Medical Research Council
Funding Amount
$680,489.00
Summary
Herbal medicines play a prominent role in traditional medicine to treat affective disorders (mood and anxiety disorders), however scientific studies are needed to truly assess their effectiveness. This clinical trial is examining the anxiolytic efficacy of Kava in treating chronic anxiety. As current response to antidepressant drugs can be inadequate, Kava may offer an additional affordable, safe, and effective option to reduce anxiety.
Novel Cellular Trafficking Mechanisms For The Drug Influx Transporter, Human Organic Anion Transporting Polypeptide 1A2 (OATP1A2)
Funder
National Health and Medical Research Council
Funding Amount
$337,614.00
Summary
Human organic anion transporting polypeptides (OATPs) are membrane proteins that regulate the cellular uptake of endogenous and exogenous substances including anti-cancer drugs. OATPs strongly determine whether such drugs enter the tissues where they are required to exert their effects. This project will study novel mechanisms that we have recently identified that determine the orientation of transporters in the cells. These processes can be impaired by a common pharmacogenetic variant in indivi ....Human organic anion transporting polypeptides (OATPs) are membrane proteins that regulate the cellular uptake of endogenous and exogenous substances including anti-cancer drugs. OATPs strongly determine whether such drugs enter the tissues where they are required to exert their effects. This project will study novel mechanisms that we have recently identified that determine the orientation of transporters in the cells. These processes can be impaired by a common pharmacogenetic variant in individuals.Read moreRead less
Medicines are not effective in all people and harmful effects from normal doses can cause suffering and even death. Ethnicity due to genetic factors can cause some medicines to be ineffective or toxic. There is little knowledge on drug genetics of Aboriginal people in contrast to Caucasians. We will study all the major drug genetic factors in groups of Aboriginal people and compare this to other ethnicities to inform physicians as to the optimal drug and dose to prescribe Aboriginal people.
Targetting Deregulated Signalling Pathways In High-grade Serous Ovarian Cancer: Defining Therapeutic Response And Mechanisms Of Resistance
Funder
National Health and Medical Research Council
Funding Amount
$641,263.00
Summary
Ovarian cancer is the major cause of death from gynaecological cancer. Most patients present with advanced disease and die of their cancer. This proposal aims to use new research detailing the common genetic changes in tumour samples and our extensive panel of ovarian cancer cell lines to identify new treatment options for specific types of ovarian cancer. We expect this will result in clinical trials of therapies selected based on the characteristics of an individual patient’s disease.
A Multi-site Study Of Tamoxifen Dose Escalation Study In Breast Cancer Patients With CYP2D6 Polymorphisms (TADE Study)
Funder
National Health and Medical Research Council
Funding Amount
$340,768.00
Summary
Tamoxifen is a selective anti-oestrogenic medication commonly used to treat breast cancer. Recent evidence suggests that tamoxifen may not be adequately activated in the body of some people because of their genetic make-up, and that this may reduce its effectiveness. In this study of 120 women, we will determine whether increasing tamoxifen dosage is a useful strategy in people with low activation levels. This could provide practical guidance for patients and clinicians managing breast cancer.
TIR Signalling Pathway Pharmacogenomics And Opioid Response: Beyond The Mu Opioid Receptor
Funder
National Health and Medical Research Council
Funding Amount
$246,396.00
Summary
This project will identify why some people respond poorly and others have toxic side effects to the major group of pain relieving medications, the opioids. The basis will be the genetics of the immune system and both acute postoperative and chronic cancer pain patients will be studied in this international pharmacogenetics project.
Clinical Implications Of IL7R Genotype: From Disease Risk To Disease Management
Funder
National Health and Medical Research Council
Funding Amount
$627,765.00
Summary
We’ve identified a genetic test (IL7R?) that may predict and prevent the risk of patients (i) failing to respond adequately to treatment for HIV (ii) who are at high risk of death after bone marrow transplantation and (iii) who fail to respond to interferon treatment for MS. This project aims to confirm these in very large patient groups and uncover the cellular basis for the genetic effect. Our goal is to provide a novel test that will improve patient outcomes in 3 serious disease states.